Neuronal induction and bioenergetics characterization of human forearm adipose stem cells from Parkinson's disease patients and healthy controls.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 13 12 2021
accepted: 26 02 2022
entrez: 15 3 2022
pubmed: 16 3 2022
medline: 4 5 2022
Statut: epublish

Résumé

Neurodegenerative diseases, such as Parkinson's disease, are heterogeneous disorders with a multifactorial nature involving impaired bioenergetics. Stem-regenerative medicine and bioenergetics have been proposed as promising therapeutic targets in the neurologic field. The rationale of the present study was to assess the potential of human-derived adipose stem cells (hASCs) to transdifferentiate into neuronal-like cells (NhASCs and neurospheres) and explore the hASC bioenergetic profile. hASC neuronal transdifferentiation was performed through neurobasal media and differentiation factor exposure. High resolution respirometry was assessed. Increased MAP-2 neuronal marker protein expression upon neuronal induction (p<0.05 undifferentiated hASCs vs. 28-36 days of differentiation) and increased bIII-tubulin neuronal marker protein expression upon neuronal induction (p<0.05 undifferentiated hASCs vs. 6-28-36 days of differentiation) were found. The bioenergetic profile was detectable through high-resolution respirometry approaches in hASCs but did not lead to differential oxidative capacity rates in healthy or clinically diagnosed PD-hASCs. We confirmed the capability of transdifferentiation to the neuronal-like profile of hASCs derived from the forearms of human subjects and characterized the bioenergetic profile. Suboptimal maximal respiratory capacity trends in PD were found. Neuronal induction leading to positive neuronal protein expression markers is a relevant issue that encourages the suitability of NhASC models in neurodegeneration.

Identifiants

pubmed: 35290400
doi: 10.1371/journal.pone.0265256
pii: PONE-D-21-39298
pmc: PMC8923468
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0265256

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Stem Cells. 2009 Oct;27(10):2509-15
pubmed: 19591229
Anal Biochem. 2011 Mar 15;410(2):310-2
pubmed: 21078286
J Neurosci Res. 2002 Sep 15;69(6):880-93
pubmed: 12205681
Am J Pathol. 2005 Jun;166(6):1841-50
pubmed: 15920168
Cell Transplant. 2019 Dec;28(1_suppl):66S-75S
pubmed: 31813268
J Neurosci Res. 2002 Sep 15;69(6):908-17
pubmed: 12205683
Handb Exp Pharmacol. 2016;233:265-82
pubmed: 25903415
Mol Ther Methods Clin Dev. 2018 Dec 06;12:134-144
pubmed: 30623002
J Neurochem. 2010 May;113(3):674-82
pubmed: 20132468
Cell Death Dis. 2017 Jan 19;8(1):e2568
pubmed: 28102844
Methods Mol Biol. 2012;810:25-58
pubmed: 22057559
Neural Regen Res. 2021 Aug;16(8):1467-1482
pubmed: 33433460
Stem Cell Reports. 2017 Mar 14;8(3):728-742
pubmed: 28216145
Methods Mol Biol. 2019;1966:237-246
pubmed: 31041752
J Neurosci Res. 2000 Aug 15;61(4):364-70
pubmed: 10931522
Mol Cell Neurosci. 2006 May-Jun;32(1-2):67-81
pubmed: 16626970
Adipocyte. 2019 Dec;8(1):164-177
pubmed: 31033391
Transl Neurodegener. 2021 Apr 29;10(1):14
pubmed: 33926570
J Cell Physiol. 2011 Mar;226(3):843-51
pubmed: 20857424
Circ Res. 2007 May 11;100(9):1249-60
pubmed: 17495232
FASEB J. 2021 Jul;35(7):e21709
pubmed: 34143518
Chin Med J (Engl). 2007 Feb 20;120(4):300-7
pubmed: 17374281
Mol Biol Cell. 2002 Dec;13(12):4279-95
pubmed: 12475952
Respir Physiol. 2001 Nov 15;128(3):277-97
pubmed: 11718759
J Transl Med. 2018 Jun 8;16(1):160
pubmed: 29884186
Neurobiol Aging. 2018 May;65:206-216
pubmed: 29501959
Am J Physiol Regul Integr Comp Physiol. 2004 Jun;286(6):R1167-75
pubmed: 15142857
Curr Drug Targets. 2005 Feb;6(1):57-62
pubmed: 15720213
Aging (Albany NY). 2019 Nov 21;11(22):10338-10355
pubmed: 31751314
Neural Regen Res. 2021 Sep;16(9):1821-1828
pubmed: 33510089
Int J Mol Sci. 2020 May 27;21(11):
pubmed: 32471255
Mol Ther Methods Clin Dev. 2021 Mar 27;21:413-433
pubmed: 33869658
Aging (Albany NY). 2019 Jun 9;11(11):3750-3767
pubmed: 31180333
Front Cell Dev Biol. 2021 Apr 30;9:658099
pubmed: 33996818
J Spinal Cord Med. 2007;30 Suppl 1:S35-40
pubmed: 17874685

Auteurs

Ingrid González-Casacuberta (I)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Dolores Vilas (D)

Neurodegenerative Diseases Unit, Neurology Service, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.

Claustre Pont-Sunyer (C)

Neurology Unit, Hospital General de Granollers, Universitat Internacional de Catalunya, Barcelona, Catalonia, Spain.

Ester Tobías (E)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Judith Cantó-Santos (J)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Laura Valls-Roca (L)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Francesc Josep García-García (FJ)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Glòria Garrabou (G)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Josep Maria Grau-Junyent (JM)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Maria Josep Martí (MJ)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Movement Disorders Unit, Neurology Service, Institut de Neurociències, University of Barcelona, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Catalonia, Spain.

Francesc Cardellach (F)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Constanza Morén (C)

Cellex-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine and Health Science, University of Barcelona, Spain.
Internal Medicine Department, Hospital Clínic of Barcelona, Barcelona, Spain.
Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH